Suppr超能文献

Dot1l 在 MLL 易位诱导的小鼠出生后造血和白血病发生中的作用。

Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation.

机构信息

Department of Pathology, University of Michigan, Ann Arbor, MI, USA.

出版信息

Blood. 2011 May 5;117(18):4759-68. doi: 10.1182/blood-2010-12-327668. Epub 2011 Feb 25.

Abstract

Disruptor of telomeric silencing 1-like (Dot1l) is a histone 3 lysine 79 methyltransferase. Studies of constitutive Dot1l knockout mice show that Dot1l is essential for embryonic development and prenatal hematopoiesis. DOT1L also interacts with translocation partners of Mixed Lineage Leukemia (MLL) gene, which is commonly translocated in human leukemia. However, the requirement of Dot1l in postnatal hematopoiesis and leukemogenesis of MLL translocation proteins has not been conclusively shown. With a conditional Dot1l knockout mouse model, we examined the consequences of Dot1l loss in postnatal hematopoiesis and MLL translocation leukemia. Deletion of Dot1l led to pancytopenia and failure of hematopoietic homeostasis, and Dot1l-deficient cells minimally reconstituted recipient bone marrow in competitive transplantation experiments. In addition, MLL-AF9 cells required Dot1l for oncogenic transformation, whereas cells with other leukemic oncogenes, such as Hoxa9/Meis1 and E2A-HLF, did not. These findings illustrate a crucial role of Dot1l in normal hematopoiesis and leukemogenesis of specific oncogenes.

摘要

端粒沉默抑制因子 1 样蛋白(Dot1l)是一种组蛋白 3 赖氨酸 79 甲基转移酶。对组成性 Dot1l 基因敲除小鼠的研究表明,Dot1l 对于胚胎发育和产前造血至关重要。DOT1L 还与混合谱系白血病(MLL)基因的易位伙伴相互作用,该基因在人类白血病中经常易位。然而,Dot1l 在 MLL 易位蛋白的后天造血和白血病发生中的作用尚未得到明确证实。利用条件性 Dot1l 基因敲除小鼠模型,我们研究了 Dot1l 缺失对后天造血和 MLL 易位白血病的影响。Dot1l 的缺失导致全血细胞减少和造血平衡的失败,并且在竞争性移植实验中,Dot1l 缺陷细胞极少重建受者骨髓。此外,MLL-AF9 细胞需要 Dot1l 才能发生致癌转化,而其他白血病致癌基因(如 Hoxa9/Meis1 和 E2A-HLF)的细胞则不需要。这些发现说明了 Dot1l 在正常造血和特定致癌基因的白血病发生中的关键作用。

相似文献

1
Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation.
Blood. 2011 May 5;117(18):4759-68. doi: 10.1182/blood-2010-12-327668. Epub 2011 Feb 25.
2
Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l.
Blood. 2013 Mar 28;121(13):2533-41. doi: 10.1182/blood-2012-11-465120. Epub 2013 Jan 29.
3
DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis.
Blood. 2011 Jun 23;117(25):6912-22. doi: 10.1182/blood-2011-02-334359. Epub 2011 Apr 26.
4
Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes.
Cancer Res. 2010 Dec 15;70(24):10234-42. doi: 10.1158/0008-5472.CAN-10-3294.
6
MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L.
Cancer Cell. 2011 Jul 12;20(1):66-78. doi: 10.1016/j.ccr.2011.06.010.
7
The emerging roles of DOT1L in leukemia and normal development.
Leukemia. 2014 Nov;28(11):2131-8. doi: 10.1038/leu.2014.169. Epub 2014 May 23.
8
Histone H2B ubiquitin ligase RNF20 is required for MLL-rearranged leukemia.
Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):3901-6. doi: 10.1073/pnas.1301045110. Epub 2013 Feb 14.
10
LEDGF/p75 is dispensable for hematopoiesis but essential for MLL-rearranged leukemogenesis.
Blood. 2018 Jan 4;131(1):95-107. doi: 10.1182/blood-2017-05-786962. Epub 2017 Oct 30.

引用本文的文献

1
The transcription factor HOXA9 induces expression of the chromatin modifier SMYD3 to drive leukemogenesis.
J Biol Chem. 2025 May 30;301(7):110320. doi: 10.1016/j.jbc.2025.110320.
2
Discovery of the first-in-class DOT1L PROTAC degrader.
Eur J Med Chem. 2025 Jul 5;291:117595. doi: 10.1016/j.ejmech.2025.117595. Epub 2025 Apr 2.
3
DOT1L Mediates Stem Cell Maintenance and Represents a Therapeutic Vulnerability in Cancer.
Cancer Res. 2025 Mar 3;85(5):838-847. doi: 10.1158/0008-5472.CAN-24-3304.
4
HOXA9 Regulome and Pharmacological Interventions in Leukemia.
Adv Exp Med Biol. 2024;1459:405-430. doi: 10.1007/978-3-031-62731-6_18.
5
An emerging maestro of immune regulation: how DOT1L orchestrates the harmonies of the immune system.
Front Immunol. 2024 Jun 19;15:1385319. doi: 10.3389/fimmu.2024.1385319. eCollection 2024.
7
Transcriptional control of leukemogenesis by the chromatin reader SGF29.
Blood. 2024 Feb 22;143(8):697-712. doi: 10.1182/blood.2023021234.
8
The emerging role of DOT1L in cell proliferation and differentiation: Friend or foe.
Histol Histopathol. 2024 Apr;39(4):425-435. doi: 10.14670/HH-18-658. Epub 2023 Aug 16.
9
The YEATS domain epigenetic reader proteins ENL and AF9 and their therapeutic value in leukemia.
Exp Hematol. 2023 Aug;124:15-21. doi: 10.1016/j.exphem.2023.06.001. Epub 2023 Jun 7.

本文引用的文献

1
Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes.
Cancer Res. 2010 Dec 15;70(24):10234-42. doi: 10.1158/0008-5472.CAN-10-3294.
2
The leukemogenic AF4-MLL fusion protein causes P-TEFb kinase activation and altered epigenetic signatures.
Leukemia. 2011 Jan;25(1):135-44. doi: 10.1038/leu.2010.249. Epub 2010 Oct 29.
3
MLL-AF9 and MLL-ENL alter the dynamic association of transcriptional regulators with genes critical for leukemia.
Exp Hematol. 2011 Jan;39(1):77-86.e1-5. doi: 10.1016/j.exphem.2010.09.003. Epub 2010 Sep 18.
4
Early mammalian erythropoiesis requires the Dot1L methyltransferase.
Blood. 2010 Nov 25;116(22):4483-91. doi: 10.1182/blood-2010-03-276501. Epub 2010 Aug 26.
5
Targeting DOT1L action and interactions in leukemia: the role of DOT1L in transformation and development.
Expert Opin Ther Targets. 2010 Apr;14(4):405-18. doi: 10.1517/14728221003623241.
6
Exploiting the balance between life and death: targeted cancer therapy and "oncogenic shock".
Biochem Pharmacol. 2010 Sep 1;80(5):666-73. doi: 10.1016/j.bcp.2010.03.001. Epub 2010 Mar 6.
7
Linking H3K79 trimethylation to Wnt signaling through a novel Dot1-containing complex (DotCom).
Genes Dev. 2010 Mar 15;24(6):574-89. doi: 10.1101/gad.1898410. Epub 2010 Mar 4.
8
The AF4.MLL fusion protein is capable of inducing ALL in mice without requirement of MLL.AF4.
Blood. 2010 Apr 29;115(17):3570-9. doi: 10.1182/blood-2009-06-229542. Epub 2010 Mar 1.
9
Histone modification levels are predictive for gene expression.
Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):2926-31. doi: 10.1073/pnas.0909344107. Epub 2010 Feb 1.
10
Misguided transcriptional elongation causes mixed lineage leukemia.
PLoS Biol. 2009 Nov;7(11):e1000249. doi: 10.1371/journal.pbio.1000249. Epub 2009 Nov 24.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验